S&P Futures
4,026.75 -9.00 (-0.22%) Dow Futures
32,691.00 -83.00 (-0.25%) Nasdaq Futures
12,835.00 -32.25 (-0.25%) Russell 2000 Futures
1,789.00 -4.30 (-0.24%) Crude Oil
69.10 -0.57 (-0.82%) Gold
1,943.80 +2.70 (+0.14%)
After hours:
Chart Events
Performance Outlook
| Previous Close | 29.70 |
| Open | 30.00 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 29.58 - 31.01 |
| 52 Week Range | 6.03 - 35.26 |
| Volume | |
| Avg. Volume | 400,352 |
| Market Cap | 1.42B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Arcellx to Participate at the H.C. Wainwright Cell Therapy Virtual Conference
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, February 28, 2023, at 1:00 p.m. ET.
- PR Newswire
Arcellx to Participate in Upcoming Investor Conferences
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the company's participation in the following investor conferences:
- Business Wire
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
SANTA MONICA, Calif. & REDWOOD CITY, Calif., January 30, 2023--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, sa
